Agilent provides xCELLigence impedance-based, label-free, real time cell analysis system and NovoCyte flow cytometers.
Discover
Related topics
Cesium-137 versus X-ray irradiation preconditioning in immunodeficient NOG mice
Dec 29, 2020
Radio-active sources have been used routinely for the preconditioning in humanized mouse models, but safety issues have...
Coming in spring 2021, meet the Cytek Aurora CS
Dec 18, 2020
Ever wanted to take your full spectrum panel from your Cytek Aurora or Northern Lights cytometer and sort? Soon, you...
Do you have our CellRad benchtop irradiator? It’s the only one on the market!
Dec 9, 2020
The CellRad is a smaller, simpler, safer, and more cost effective alternative to radioisotope or high-powered X-ray...
Discover the new NovoCyte Penteon - when exceptional performance meets simplicity
Nov 18, 2020
The NovoCyte Penteon flow cytometer builds on its successful predecessor, the NovoCyte. You now have the flexibility to...
Introducing the GenapSys Sequencer
Apr 15, 2020
GenapSys has developed a novel electrical-based platform capable of accurately detecting single base incorporations....
IncuCyte neuronal activity assay
Nov 13, 2018
The generation and maturation of neuronal networks are necessary characteristics of neurogenesis, providing...
COY - personalized hypoxic chambers
Oct 18, 2018
When your research requires consistent atmospheric control to maintain hypoxia, normoxia, or hyperoxia, you can count...
Coy anaerobic chambers #1 choice in microbiology
Oct 5, 2018
Used for over 40 years in anaerobic microbiology research, COY chambers are also critical to many other research areas...
ACEA Biosciences introduces an exploratory xCELLigence RTCA S16 instrument
Aug 30, 2018
The company has just introduced the xCELLigence RTCA S16, which is the ideal entry level model for exploratory studies...
Aug 23, 2018
The new X-RAD 160 qube is suitable for either mounting on the lab bench or mobile on an optional wheeled cart, allowing...
Aug 1, 2016
ACEA Biosciences, a pioneer in the development of high performance cell analysis platforms including the xCELLigence Real-Time Cell Analyzer (RTCA) instruments and NovoCyte flow cytometers, is introducing an immunotherapy kit for in vitro monitoring and quantification of effector-mediated B cell killing. This kit enables continuous real-time monitoring of B cell lymphomas as they are exposed to diverse immunotherapy approaches including NK cells, T cells, CARTs, oncolytic virus, checkpoint inhibitors, bispecific antibodies, BiTEs, etc. The major distinguishing features of this technology include enhanced sensitivity, the preclusion of labels, simple workflow and, importantly, continuous kinetic measurement of B cell cytolysis. This B cell-specific kit is the first in a series of xCELLigence immunotherapy-focused kits that ACEA will be launching in the coming months.
The utility of impedance-based xCELLigence Real-Time Cell Analysis (RTCA) for probing the efficacy of immunotherapies targeting solid/adherent cancers has been firmly established over the past decade. However, ~10% of all cancers are liquid in nature, are non-adherent and therefore cannot be directly monitored by the standard impedance assay. The B Cell Killing Assay Kit contains reagents which enable B cells to be selectively immobilized in the well bottoms of ACEA’s electronic microtiter plates. Addition of effector cells (NK, T, CART) on top of immobilized B cells results in cytolysis of target cells in an effector concentration-dependent manner. The continuous acquisition of impedance data for each well of the electronic plate allows the generation of real-time killing curves for multiple conditions simultaneously.
Dr. Yama Abassi, Vice President of ACEA Biosciences, noted that “The xCELLigence instruments provide a quantitative kinetic assessment of immune cell-mediated killing of both solid and liquid tumor cells under label-free conditions.” He further stated that “This functional assay is currently being used for evaluating/optimizing combination therapies, and for the development of adoptive cell therapies and engineered antibodies. Beyond the arena of R&D, we envision xCELLigence being utilized as a quality control assay for manufactured immuno-oncology therapies.”
Related technologies: Conventional flow cytometry
Brand profile
Agilent provides xCELLigence impedance-based, label-free, real time cell analysis system and NovoCyte flow cytometers.
More info at:
www.aceabio.com